

Edgar Filing: H&Q HEALTHCARE INVESTORS - Form 13F-HR

H&Q HEALTHCARE INVESTORS

Form 13F-HR

October 17, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 13F

Form 13F COVER PAGE

Report for the Calendar Year or Quarter Ended: 9/30/02

Check Here if Amendment / /; Amendment Number: -----

This Amendment (Check only one.): / / is a restatement.
/ / adds new holdings entries.

Institutional Investment Manager Filing this Report:

Name: Hambrecht & Quist Capital Management LLC

Address: 30 Rowes Wharf

Boston, MA 02110

Form 13F File Number: 28-04219

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:

Name: Kim Carroll

Title: Treasurer

Phone: 617-772-8525

Signature, Place, and Date of Signing:
Kim Carroll Boston, MA 10/18/02

[Signature] [City, State] [Date]

Report Type (Check only one.):

/X/ 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)

Edgar Filing: H&Q HEALTHCARE INVESTORS - Form 13F-HR

/ / 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)

/ / 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

| ITEM 1: NAME OF ISSUER | | ITEM 2: TITLE OF CLASS | ITEM 3: CUSIP NUMBER | ITEM 4: FAIR MARKET VALUE | ITEM 5: SHARES OF PRINCIPAL (a) | ITEM 6: INVESTMENT DISCRETION (b) SHARED- AS DEFINED IN (c) INSTR. V | SHARED OTHER |
|--------------------------------|--------|---------------------------------|----------------------------|------------------------------------|---------------------------------------|---|-----------------|
| Abgenix | Common | 00039B107 | \$3,212,550 | 495,000 | X | | |
| Adolor | Common | 00724X102 | \$7,263,762 | 518,100 | X | | |
| Aradigm | Common | 038505103 | 735,000 | 350,000 | X | | |
| Biofield | Common | 090591207 | 351,547 | 878,866 | X | | |
| Biofield (Restricted) | Common | 090591207 | 320,000 | 1,000,000 | X | | |
| Biopure | Common | 09065H915 | 594,111 | 169,746 | X | | |
| BioTransplant | Common | 09066Y107 | 1,239,782 | 712,518 | X | | |
| Catalytica Energy Systems | Common | 148884109 | 445,947 | 128,515 | X | | |
| Celgene | Common | 151020104 | 11,619,600 | 690,000 | X | | |
| Cephalon | Common | 156708109 | 3,673,800 | 90,000 | X | | |
| Corixa | Common | 21887F100 | 4,536,059 | 716,597 | X | | |
| Cubist Pharmaceuticals | Common | 229990981 | 4,895,405 | 958,005 | X | | |
| CV Therapeutics | Common | 126667104 | 11,423,279 | 546,307 | X | | |
| Cytc | Common | 232946103 | 4,655,546 | 434,286 | X | | |
| deCODE Genetics | Common | 24386104 | 1,639,000 | 745,000 | X | | |
| Digene | Common | 253752109 | 217,250 | 27,500 | X | | |
| Dyax | Common | 26746E103 | 1,346,874 | 694,265 | X | | |
| Endocardial Solutions | Common | 292962107 | 5,383,331 | 1,666,666 | X | | |
| Endologix | Common | 292665106 | 330,000 | 330,000 | X | | |
| Envirogen | Common | 294040100 | 11,250 | 20,833 | X | | |
| EP MedSystems | Common | 26881P103 | 2,150,000 | 1,075,000 | X | | |
| Exelixis | Common | 30161Q104 | 6,048,900 | 1,222,000 | X | | |
| Genzyme | Common | 372917104 | 5,544,090 | 269,000 | X | | |
| Gilead Sciences | Common | 37555B103 | 24,364,105 | 726,636 | X | | |
| IDEXX Laboratories | Common | 45168D104 | 7,737,000 | 250,000 | X | | |
| IVAX | Common | 465823102 | 4,392,660 | 358,000 | X | | |
| Lexicon Genetics | Common | 288872104 | 743,855 | 185,500 | X | | |
| Lynx Therapeutics | Common | 551812308 | 1,349,800 | 1,985,000 | X | | |
| Martek Biosciences | Common | 572901106 | 12,780,069 | 780,224 | X | | |
| MedImmune | Common | 584699102 | 6,903,600 | 330,000 | X | | |
| Molecular Devices | Common | 60851C107 | 3,637,508 | 290,768 | X | | |
| Orthovita | Common | 68750U102 | 4,675,000 | 1,700,000 | X | | |
| Quintiles Transnational | Common | 748767100 | 1,454,079 | 152,900 | X | | |
| Rigel Pharmaceuticals | Common | 766559108 | 1,644,000 | 1,027,500 | X | | |
| Telik | Common | 87959M109 | 8,253,313 | 666,665 | X | | |
| Teva Pharmaceutical Industries | Common | 881624209 | 6,700,000 | 100,000 | X | | |
| Transkaryotic Therapies | Common | 893735100 | 12,398,446 | 382,550 | X | | |
| Tularik | Common | 899165104 | 2,777,025 | 405,405 | X | | |
| Versicor | Common | 925314106 | 5,937,938 | 696,941 | X | | |

Edgar Filing: H&Q HEALTHCARE INVESTORS - Form 13F-HR

| | | | | | |
|------------------------|--------|-----------|-----------|---------------|---|
| Vertex Pharmaceuticals | Common | 92532F100 | 3,507,553 | 189,700 | X |
| WebMD | Common | 94769M105 | 3,825,375 | 757,500 | X |
| COLUMN TOTALS | | | | \$190,718,409 | |